Similar articles

• Infliximab in a case of early adult-onset Still's disease.

  Olivieri I, de Stefano G, Padula A, La Gala A, de Stefano C. Olivieri I, et al. Clin Rheumatol. 2003 Oct;22(4-5):369-70. doi: 10.1007/s10067-003-0744-z. Clin Rheumatol. 2003. PMID: 14579170 No abstract available.
• Is rituximab effective as a single agent in mantle-cell lymphoma?

  Grillo-López AJ. Grillo-López AJ. Nat Clin Pract Oncol. 2005 Oct;2(10):500-1. doi: 10.1038/ncponc0297. Nat Clin Pract Oncol. 2005. PMID: 16205768 Clinical Trial. No abstract available.
• Infusion reactions triggered by monoclonal antibodies treating solid tumors.

  Carney PH, Ollom CL. Carney PH, et al. J Infus Nurs. 2008 Mar-Apr;31(2):74-83. doi: 10.1097/01.NAN.0000313654.57786.bb. J Infus Nurs. 2008. PMID: 18344767 Review.
• Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis.

  Chu Miow Lin D, Mulleman D, Azzopardi N, Griffoul-Espitalier I, Valat JP, Paintaud G, Goupille P. Chu Miow Lin D, et al. Scand J Rheumatol. 2010;39(1):97-8. doi: 10.3109/03009740903177745. Scand J Rheumatol. 2010. PMID: 20132079 No abstract available.
• Keys to unlock cancer: targeted therapy.

  Viele CS. Viele CS. Oncol Nurs Forum. 2005 Sep 1;32(5):935-40. doi: 10.1188/05.ONF.935-940. Oncol Nurs Forum. 2005. PMID: 16136192 Review. No abstract available.